This was found on March 24 in AstraZeneca's Open Innovation...

This was found on March 24 in AstraZeneca's Open Innovation Website

https://openinnovation.astrazeneca.com/preclinical-research/preclinical-molecules/azd4320.html

For those that do not remember AZD4320 was poisonous, but our technology platform conjugating dendrimers to formulate AZD0466 worked and was used initially in solid cancers. AstraZeneca in it's wisdom decided to change from solid cancers to blood cancers which needed much higher doses to work. The study was stopped due to adverse effects in those much higher doses

However as indicated in an earlier post solid cancers required much lower doses. The study for solid cancers was terminated for strategic reasons. Those strategic reasons was to use AZD0466 in blood cancers where there was far greater demand and if it worked far greater returns

The solid cancer trial was not terminated because of any adverse effects